| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias
|
Kfoury, Maria
|
|
|
110 |
C |
p.
|
artikel
|
| 2 |
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review
|
Graham, Jeffrey
|
|
|
110 |
C |
p.
|
artikel
|
| 3 |
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis
|
Fallara, Giuseppe
|
|
|
110 |
C |
p.
|
artikel
|
| 4 |
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
|
Corrie, Pippa
|
|
|
110 |
C |
p.
|
artikel
|
| 5 |
Current state of play for HPV-positive oropharyngeal cancers
|
Deutsch, Fiona
|
|
|
110 |
C |
p.
|
artikel
|
| 6 |
Editorial Board
|
|
|
|
110 |
C |
p.
|
artikel
|
| 7 |
Hypofractionated proton therapy for non-small cell lung cancer: Ready for prime time? A systematic review and meta-analysis
|
Volpe, Stefania
|
|
|
110 |
C |
p.
|
artikel
|
| 8 |
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
|
Fujiwara, Yu
|
|
|
110 |
C |
p.
|
artikel
|
| 9 |
Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
|
Iyer, Kirti K.
|
|
|
110 |
C |
p.
|
artikel
|
| 10 |
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
|
Bonadio, Renata Colombo
|
|
|
110 |
C |
p.
|
artikel
|
| 11 |
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis
|
Musacchio, Lucia
|
|
|
110 |
C |
p.
|
artikel
|
| 12 |
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?
|
Miglietta, Federica
|
|
|
110 |
C |
p.
|
artikel
|
| 13 |
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision
|
Lai, Gillianne G.Y.
|
|
|
110 |
C |
p.
|
artikel
|
| 14 |
Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer
|
Akin Telli, Tugba
|
|
|
110 |
C |
p.
|
artikel
|
| 15 |
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
|
Stacchiotti, Silvia
|
|
|
110 |
C |
p.
|
artikel
|
| 16 |
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?
|
Cucciniello, Linda
|
|
|
110 |
C |
p.
|
artikel
|
| 17 |
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
|
Garufi, Giovanna
|
|
|
110 |
C |
p.
|
artikel
|
| 18 |
Treatment strategies for patients with diffuse large B-cell lymphoma
|
Poletto, Stefano
|
|
|
110 |
C |
p.
|
artikel
|
Tijdschrift beschrijving